Acessibilidade / Reportar erro
Short Communication • Rev. Soc. Bras. Med. Trop. 53 • 2020 • https://doi.org/10.1590/0037-8682-0594-2019   copy

Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil

Authorship SCIMAGO INSTITUTIONS RANKINGS

Abstract

INTRODUCTION

We conducted a cost-utility analysis of available interferon-free treatments for patients with early-stage genotype 1 chronic hepatitis C based on a Brazilian public health system perspective.

METHODS

A Markov model was derived using a cohort of stage F0-F2 patients treated as recommended by the Brazilian national guidelines.

RESULTS:

Glecaprevir plus pibrentasvir was superior to all other treatments, followed by sofosbuvir plus velpatasvir. Sofosbuvir plus daclatasvir was identified as the least cost-effective option.

CONCLUSIONS:

The above findings were confirmed via probabilistic sensitivity analysis and the tested scenarios.

Keywords:
Hepatitis C; Cost-effectiveness analysis; Treatment; Brazil

Sociedade Brasileira de Medicina Tropical - SBMT Caixa Postal 118, 38001-970 Uberaba MG Brazil, Tel.: +55 34 3318-5255 / +55 34 3318-5636/ +55 34 3318-5287, http://rsbmt.org.br/ - Uberaba - MG - Brazil
E-mail: rsbmt@uftm.edu.br
Acompanhe os números deste periódico no seu leitor de RSS